Literature DB >> 27256140

Liver regeneration following repeated reversible portal vein embolization in an experimental model.

H Tranchart1,2,3,4, G M Koffi1,2,3, M Gaillard1,2,3,4, P Lainas1,2,3,4, C Poüs5, P Gonin6, T H Nguyen7, A Dubart-Kupperschmitt1,2,3, I Dagher1,2,3,4.   

Abstract

BACKGROUND: Portal vein embolization (PVE) is used routinely to prevent postoperative liver failure as a result of anticipated insufficient future liver remnant volume following resection. The authors have recently developed a technique for temporary PVE. The aim of this study was to assess the effect of repeated reversible PVE on hepatocyte proliferation and subsequent liver hypertrophy in rodents.
METHODS: Four treatments were compared (n = 21 rats per group): single reversible PVE, two PVEs separated by 14 days, partial portal vein ligation or sham procedure. The feasibility and tolerance of the procedure were assessed. Volumetric imaging by CT was used to estimate the evolution of liver volumes. After death, the weight of liver lobes was measured and hepatocyte proliferation evaluated by immunostaining.
RESULTS: Embolization of portal branches corresponding to 70 per cent of total portal flow was performed successfully in all animals. Repeated PVE induced additional hepatocyte proliferation. Repeated embolization resulted in superior hepatocyte proliferation in the non-occluded segments compared with portal vein ligation (31·1 versus 22·2 per cent; P = 0·003). The non-occluded to total liver volume ratio was higher in the repeated PVE group than in the single PVE and sham groups (P = 0·050 and P = 0·001 respectively).
CONCLUSION: Repeated reversible PVE successfully induced additional hepatocyte proliferation and subsequent liver hypertrophy. Surgical relevance Portal vein embolization (PVE) is used routinely to prevent postoperative liver failure as a result of anticipated insufficient future liver remnant volume following resection. In the present study, a technique of repeated temporary PVE was developed in a rat model; this induced additional hepatocyte proliferation and an increase in liver volume compared with single embolization. This novel approach might help induce major hypertrophy of the future remnant liver, which could increase the rate of patients amenable to major liver resections.
© 2016 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27256140     DOI: 10.1002/bjs.10153

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  5 in total

Review 1.  Optimization of the future remnant liver: review of the current strategies in Europe.

Authors:  Riccardo Memeo; Maria Conticchio; Emmanuel Deshayes; Silvio Nadalin; Astrid Herrero; Boris Guiu; Fabrizio Panaro
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

2.  Functional shift with maintained regenerative potential following portal vein ligation.

Authors:  Tibor Kovács; Domokos Máthé; András Fülöp; Katalin Jemnitz; Attila Bátai-Konczos; Zsuzsanna Veres; György Török; Dániel Sándor Veres; Ildikó Horváth; Krisztián Szigeti; László Homolya; Attila Szijártó
Journal:  Sci Rep       Date:  2017-12-22       Impact factor: 4.379

Review 3.  Neoadjuvant treatment strategies for hepatocellular carcinoma.

Authors:  Lei Xu; Lin Chen; Wei Zhang
Journal:  World J Gastrointest Surg       Date:  2021-12-27

4.  Endoscopic injection sclerotherapy improves liver function compared with endoscopic variceal ligation.

Authors:  Tsuguru Hayashi; Tatsuyuki Watanabe; Michihiko Shibata; Shinsuke Kumei; Shinji Oe; Koichiro Miyagawa; Yuichi Honma; Masaru Harada
Journal:  Sci Rep       Date:  2021-10-14       Impact factor: 4.379

Review 5.  Current strategies to induce liver remnant hypertrophy before major liver resection.

Authors:  Celeste Del Basso; Martin Gaillard; Panagiotis Lainas; Stella Zervaki; Gabriel Perlemuter; Pierre Chagué; Laurence Rocher; Cosmin Sebastian Voican; Ibrahim Dagher; Hadrien Tranchart
Journal:  World J Hepatol       Date:  2021-11-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.